[ALNY] Alnylam Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 41.29 Change: 1.9 (4.82%)
Ext. hours: Change: 0 (0%)

chart ALNY

Refresh chart

Strongest Trends Summary For ALNY

ALNY is in the long-term up 377% in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-CC5 for the treatment of complement-mediated diseases; ALN-AS1 for the treatment of hepatic porphyrias; ALN-PCS for the treatment of hypercholesterolemia; ALN-AAT for the treatment of AAT deficiency liver disease; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-ANG for the treatment of genetic forms of mixed hyperlipidemia and severe hypertriglyceridemia; and other programs. The company?s partner-based product development clinical and pre-clinical programs comprise ALN-RSV01 for the treatment of respiratory syncytial virus infection; ALN-VSP for the treatment of liver

Fundamental Ratios
Shares Outstanding EPS-4.83 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 154.11% Sales Growth - Q/Q-22.82% P/E-15.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-9.84% ROE-10.71% ROI
Current Ratio13.51 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin-309.32% Net Profit Margin-263.44% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities598.98 M Cash From Investing Activities-341.33 M Cash From Operating Activities-26.25 M Gross Profit
Net Profit-50.78 M Operating Profit-52.22 M Total Assets1.63 B Total Current Assets1.09 B
Total Current Liabilities80.69 M Total Debt Total Liabilities132.28 M Total Revenue18.54 M
Technical Data
High 52 week148.54 Low 52 week65.07 Last close73.34 Last change0.91%
RSI28.58 Average true range5.13 Beta1.23 Volume734.61 K
Simple moving average 20 days-3.14% Simple moving average 50 days-10.23% Simple moving average 200 days-27.17%
Performance Data
Performance Week5.72% Performance Month0.47% Performance Quart-24.29% Performance Half-26.65%
Performance Year-44.58% Performance Year-to-date-42.27% Volatility daily4.85% Volatility weekly10.84%
Volatility monthly22.22% Volatility yearly76.97% Relative Volume208.92% Average Volume940.78 K
New High New Low


2020-06-01 07:00:00 | Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA International Congress

2020-05-27 09:47:01 | Alnylam's ALNY Lumasiran NDA Gets Priority Review From FDA

2020-05-26 16:00:00 | Alnylam to Webcast Presentations at Upcoming June Investor Conferences

2020-05-26 07:00:00 | Alnylam Announces U.S. Food and Drug Administration Has Granted Priority Review of the Lumasiran New Drug Application for the Treatment of Primary Hyperoxaluria Type 1

2020-05-25 11:30:03 | Is Alnylam Pharmaceuticals ALNY Outperforming Other Medical Stocks This Year?

2020-05-22 12:30:00 | Alnylam Presents New Long-Term Results from Global Open-Label Extension Study of ONPATTRO® patisiran at the European Academy of Neurology Virtual Congress 2020

2020-05-21 07:03:00 | Is Alnylam Pharmaceuticals a Buy?

2020-05-12 16:01:10 | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results

2020-05-11 10:46:02 | How Alnylam ALNY Stock Stands Out in a Strong Industry

2020-05-11 08:00:00 | Alnylam to Webcast Presentations at Upcoming May Investor Conferences

2020-05-07 12:00:04 | What Makes Alnylam ALNY a New Buy Stock

2020-05-07 11:30:03 | Is Alnylam Pharmaceuticals ALNY Outperforming Other Medical Stocks This Year?

2020-05-07 10:25:02 | Alnylam ALNY Beats on Q1 Earnings, Cuts Onpattro Sales View

2020-05-06 19:46:42 | Edited Transcript of ALNY earnings conference call or presentation 6-May-20 12:30pm GMT

2020-05-06 18:30:53 | Alnylam Pharmaceuticals Inc ALNY Q1 2020 Earnings Call Transcript

2020-05-06 13:27:00 | Alnylam Pharmaceuticals Lowers 2020 Sales Expectations Due to COVID-19

2020-05-06 09:25:01 | Alnylam Pharmaceuticals ALNY Reports Q1 Loss, Tops Revenue Estimates

2020-05-06 08:00:00 | Alnylam Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Period Activity

2020-05-05 11:45:03 | Drug/Biotech Stock Q1 Earnings Due on May 6: ZTS, ALXN & More

2020-05-05 11:40:03 | 5 Drug/Biotech Stocks Set to Outpace Q1 Earnings Estimates

2020-05-05 10:40:02 | Is a Surprise Coming for Alnylam Pharmaceuticals ALNY This Earnings Season?

2020-05-04 10:23:00 | Vir Biotechnology and Alnylam Pick a Coronavirus Vaccine Candidate to Pursue

2020-05-04 08:24:57 | Vir, Alnylam identify COVID-19 therapy candidate, plan human trials by year end

2020-05-04 07:46:11 | Vir, Alnylam pick coronavirus therapy candidate, plan human trials by year end

2020-05-04 07:30:00 | Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 ALN-COV, Targeting SARS-CoV-2 for the Treatment of COVID-19

2020-05-03 08:37:53 | If You Had Bought Alnylam Pharmaceuticals NASDAQ:ALNY Stock Three Years Ago, You Could Pocket A 134% Gain Today

2020-04-29 12:34:04 | Alnylam Pharmaceuticals ALNY Expected to Beat Earnings Estimates: Should You Buy?

2020-04-23 08:00:00 | Alnylam to Webcast Conference Call Discussing First Quarter 2020 Financial Results

2020-04-17 16:23:00 | Blackstone’s Byron Wien Weighs In on Employment, China, and the Health-Care System

2020-04-16 06:35:12 | These Mass. companies are developing COVID-19 treatments and tests

2020-04-15 16:01:10 | VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial

2020-04-15 11:15:03 | Alnylam's Vutrisiran Gets Fast Track Tag for hATTR Amyloidosis

2020-04-14 10:06:02 | Alnylam's $2B Deal With Blackstone to Boost Drug Development

2020-04-14 07:00:00 | Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis

2020-04-13 16:00:00 | Alnylam to Webcast Presentation at 19th Annual Needham Virtual Healthcare Conference

2020-04-13 14:57:56 | Alnylam plans Cambridge expansion after $2B investment

2020-04-13 07:46:00 | Blackstone invests $2 billion in Alnylam, boosting gene-silencing drug development

2020-04-13 07:43:00 | Alnylam Rises on $2 Billion Blackstone Investment

2020-04-13 07:41:52 | Blackstone invests $2 bln in Alnylam Pharma

2020-04-13 07:35:00 | Alnylam's stock surges after Blackstone confirms $2 billion investment

2020-04-13 07:30:00 | Blackstone and Alnylam Enter Into $2 Billion Strategic Financing Collaboration to Accelerate the Advancement of RNAi Therapeutics

2020-04-13 01:23:59 | Blackstone/Alnylam: royalty flush

2020-04-09 08:00:19 | Is Pfizer Stock A Buy As It Partners On A Potential Coronavirus Vaccine?

2020-04-08 11:19:47 | Vir Biotech Adds Glaxo to List of Covid-19 Partners

2020-04-08 10:24:02 | Alnylam ALNY Completes Rolling Submission of Lumasiran NDA

2020-04-08 10:05:02 | Biotech Stock Roundup: AMGN & INCY Focus on Coronavirus Treatments, & More

2020-04-07 07:00:00 | Alnylam Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration and Submits Marketing Authorization Application to the European Medicines Agency for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1

2020-04-06 18:26:17 | Alnylam, Dicerna Join Forces to Take on Arrowhead

2020-04-06 10:30:48 | Former gene-silencing rivals bury the hatchet with new partnership

2020-04-06 07:00:00 | Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs